Xilio Therapeutics to Present at Society for Immunotherapy of …

Xilio Therapeutics, a clinical-stage biotechnology company developing tumor-specific T cell immunotherapies for solid tumors, has recently announced the successful completion of a Series C financing round, raising $102 million. The funding will be utilized to advance the company’s lead programs towards clinical development and expand its proprietary pipeline of therapeutic candidates.

The oversubscribed financing round was led by RA Capital Management, with participation from additional new investors and existing investors. The strong support from investors reflects confidence in Xilio’s innovative approach to developing cancer therapies that harness the power of the immune system to target and destroy solid tumors.

Xilio Therapeutics is focused on addressing the challenges associated with current cancer treatments, particularly for patients with solid tumors that are resistant to existing therapies. By leveraging its proprietary technology platform, Xilio aims to develop next-generation immunotherapies that are designed to be more efficacious and safer for patients.

CEO of Xilio Therapeutics, René Russo, expressed gratitude for the support from investors and highlighted the company’s commitment to advancing its groundbreaking therapies towards clinical development. “This financing round provides us with the resources to accelerate the development of our lead programs and drive our mission of transforming the treatment of cancer,” Russo stated.

The company’s lead product candidate, XTX101, is a tumor-specific T cell therapy designed to target a broad range of solid tumors. XTX101 has shown promising preclinical results, demonstrating its potential to effectively target and eradicate tumor cells while sparing healthy tissues. Xilio Therapeutics is eager to advance XTX101 into clinical trials to evaluate its safety and efficacy in patients with solid tumors.

In addition to advancing its lead programs, Xilio Therapeutics intends to use the funding to further expand its pipeline of novel therapeutic candidates. The company is dedicated to exploring innovative approaches to cancer treatment and is actively pursuing the development of new immunotherapies that can address unmet medical needs in oncology.

The successful completion of the Series C financing round marks a significant milestone for Xilio Therapeutics, positioning the company for continued growth and advancement in the field of cancer immunotherapy. With a strong focus on innovation and a commitment to improving outcomes for cancer patients, Xilio is poised to make a meaningful impact in the fight against cancer.